Shares in GSK (GSK -0.6%), Pfizer (PFE +0.3%) and Abbott (ABT +0.2%) show little reaction to...
Shares in GSK (GSK -0.6%), Pfizer (PFE +0.3%) and Abbott (ABT +0.2%) show little reaction to news that lamivudine and zidovudine, which they sell in a JV, helped cure a 2/12 year old infant of HIV. Other firms that develop HIV treatments, including Merck (MRK +0.4%), J&J (JNJ +0.35%) and Gilead (GILD +0.3%), also don't seem too impressed.
From other sites
Video at CNBC.com (Fri, 4:24PM)
Video at CNBC.com (Fri, 1:14PM)
Video at CNBC.com (Fri, 11:40AM)
at CNBC.com (May 28, 2015)
Video at CNBC.com (May 11, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs